HKPMDC
 All     Test   
 
Pharmacogenomics
Others


Test Name: HLA-B*1502 Genotyping for Carbamazepine Treatment
Compliance:CE-IVD
Test Description:HLA-B*1502 allele is strongly associated with Carbamazepine (CBZ)-induced Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients of Asian descent.
Methodology:Real-time PCR detection of HLA-B*1502 allele
Gene Name:

HLA-B
Protein Name:
Specimen Requirements:EDTA Blood (5mL)
Storage Condition:Ambient Temperature / 4℃ (if overnight is needed)
Turn Around Time:5 working days from day of specimen received
OMIM:
Genetic Home Reference:
Phone: +852.2986.1213
Fax:+852.2527.7028
E-mail:contact@hk-mpdc.com
35/F, Enterprise Square Two, 3 Sheung Yuet Road, Kowloon Bay, Hong Kong
Opening Hours
Mondays to Fridays: 09:00-18:00
Saturdays: 09:00-16:00
Sundays and Public Holidays: Closed

For specimen pickup arrangements, please phone +852.2986.1213


Shipping & Billing Information

HOKLAS accreditation scope

Non-disclosure and Complaints
All data/information generated from within/related to HKMPDC and our customers are treated in strict confidence in accordance with the Personal Data (Privacy) Ordinance of Hong Kong. If you have a complaint, please contact us at the (852) 2986 1213 or email us at contact@hk-mpdc.com. All communications with HKMPDC would be dealt with in strict confidence.

Notice of Privacy Practices
This notice describes how medical information about you may be used and disclosed.
Personal health information or related information released to HKMPDC relating to the services requested may be subjected to re-disclosure by HKMPDC to health care providers, such as doctors, nurses, and others involved in the delivery of the services.
We may also disclose medical information about you to authorised public health or government officials for public health activities as required by law and accreditation body.

Copyright © 2013 香港分子病理檢驗中心 Hong Kong Molecular Pathology Diagnostic Centre Limited (HKMPDC). All Rights Reserved.

Information Updated 1 July, 2023.